Nitnib 50 Capsule

Prezentare produs

About Nitnib 50

Nitnib 50 is a medication containing the active ingredient Sunitinib, classified as Cancer medication. Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE Sunitinib malate is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST).
• Used for: 1 ) treatment of adult patients with advanced renal cell carcinoma (RCC)
• Use only as directed on the product label or by a healthcare professional.

Active Ingredient & Action

Sunitinib, the active ingredient in Nitnib 50, belongs to the Cancer medication class. 1 INDICATIONS AND USAGE Sunitinib malate is a kinase inhibitor indicated for: treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1. 1 ) treatment of adult patients with advanced renal cell carcinoma (RCC). Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Nitnib 50. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Nitnib 50 for extended periods without medical advice.